Clinical Trial · NCT02523924

Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

Overview

This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase

N/A

ClinicalTrials.gov

NCT02523924

Drug / Compound

DCFPyL

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

Serum PSA level ≥0.2 ng/mL at least 45 days prior to study enrollment
Completed staging evaluation with bone scan as well as CT or MRI of the abdomen and pelvis at least 45 days prior to study enrollment
History of adenocarcinoma of the prostate treated with radical prostatectomy

Exclusion

Intention to enroll in a blinded therapeutic clinical trial
History of other malignancy diagnosed within the last three years (the exception of squamous cell or basal cell carcinoma of the skin)